Tuesday, October 6, 2009

Transdel Pharmaceuticals announces positive Phase 3 study results for Lead Topical Pain Drug Ketotransdel(R), my man

But the stock doesn't really go anywhere. Currently at $2.12.
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)